Vanguard Group Inc. Raises Stake in Heartflow, Inc. $HTFL

Vanguard Group Inc. boosted its stake in Heartflow, Inc. (NASDAQ:HTFL) by 8.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,580,313 shares of the company’s stock after purchasing an additional 128,400 shares during the quarter. Vanguard Group Inc. owned about 1.86% of Heartflow worth $46,066,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Wellington Management Group LLP acquired a new position in Heartflow during the third quarter valued at approximately $164,263,000. Baillie Gifford & Co. acquired a new position in Heartflow during the third quarter valued at approximately $101,182,000. Schusterman Interests LLC acquired a new position in Heartflow during the third quarter valued at approximately $65,274,000. Capital International Investors acquired a new position in Heartflow during the third quarter valued at approximately $43,671,000. Finally, Bamco Inc. NY acquired a new position in Heartflow during the third quarter valued at approximately $41,654,000.

Heartflow Stock Down 12.2%

Shares of HTFL opened at $28.32 on Friday. The firm has a 50-day moving average price of $27.28 and a 200 day moving average price of $28.87. The firm has a market capitalization of $2.44 billion and a PE ratio of -9.11. Heartflow, Inc. has a 52-week low of $20.13 and a 52-week high of $41.22.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.08. The business had revenue of $52.59 million during the quarter. Heartflow’s quarterly revenue was up 41.3% compared to the same quarter last year. On average, equities analysts expect that Heartflow, Inc. will post -0.78 EPS for the current year.

Insider Activity at Heartflow

In other news, major shareholder Bain Capital Life Sciences Inv sold 948,757 shares of the firm’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $29.23, for a total value of $27,732,167.11. Following the sale, the insider owned 8,448,158 shares in the company, valued at approximately $246,939,658.34. This trade represents a 10.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Campbell Rogers sold 64,533 shares of Heartflow stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $24.64, for a total value of $1,590,093.12. Following the transaction, the insider directly owned 81,002 shares of the company’s stock, valued at approximately $1,995,889.28. The trade was a 44.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,205,874 shares of company stock valued at $64,166,729 over the last ninety days. 7.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Wells Fargo & Company boosted their target price on shares of Heartflow from $35.00 to $37.00 and gave the stock an “overweight” rating in a research report on Friday. JPMorgan Chase & Co. reduced their target price on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, March 19th. William Blair assumed coverage on shares of Heartflow in a research report on Monday, May 4th. They set an “outperform” rating on the stock. Finally, Canaccord Genuity Group reduced their target price on shares of Heartflow from $43.00 to $37.00 and set a “buy” rating on the stock in a research report on Friday. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $37.00.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.